IHE - iShares US Pharmaceuticals ETF

NYSEArca - NYSEArca Delayed Price. Currency in USD
158.43
-0.37 (-0.23%)
At close: 3:59PM EDT
Stock chart is not supported by your current browser
Previous Close158.80
Open158.22
Bid0.00 x 900
Ask0.00 x 800
Day's Range157.75 - 158.43
52 Week Range139.28 - 166.06
Volume16,219
Avg. Volume9,414
Net Assets370.39M
NAV151.18
PE Ratio (TTM)N/A
Yield1.22%
YTD Return-1.29%
Beta (3y)1.00
Expense Ratio (net)0.43%
Inception Date2006-05-01
Trade prices are not sourced from all markets
  • Comparing Pharmaceuticals ETFs’ June Performance
    Market Realist13 days ago

    Comparing Pharmaceuticals ETFs’ June Performance

    Pharmaceutical ETFs, securities publicly traded on stock markets, are designed for investors who do not have the capacity to hold many stocks but are interested in diversifying their pharmaceutical investments. The chart below compares ETFs’ normalized prices in June.

  • ETF Trends16 days ago

    July Could Be a Volatile Month for Pharma ETFs

    Changing political winds and the seasonal period for drugmakers to hike their prices could trigger short-term volatility in pharmaceutical sector-related ETFs. The markets could put a spotlight on pharmaceutical stocks and the rising cost of drug prices as Mid-term elections are quickly coming up in November and July is a popular month for drug companies to increase list prices on medicines, writes Charley Grant for the Wall Street Journal. Just last week, Health and Human Services Secretary Alex Azar said in congressional testimony that companies should “practice restraint” with price increases.

  • Play the Best Sector of Summer With These ETFs & Stocks
    Zackslast month

    Play the Best Sector of Summer With These ETFs & Stocks

    Health care is apparently one of the best-performing sectors of summer. So, track these ETFs and stocks.

  • Pharmaceutical ETFs and Their Performances in May
    Market Realistlast month

    Pharmaceutical ETFs and Their Performances in May

    Pharmaceutical ETFs are securities that are publicly traded on the stock market and designed for investors wanting to diversify their investments in the pharmaceutical sector.

  • Trump lets drug companies off the hook
    Yahoo Finance2 months ago

    Trump lets drug companies off the hook

    After several delays, President Trump unveiled a plan to lower drug prices. Don't bank on it just yet.

  • Merck’s Segment-Wise Performance in 1Q18
    Market Realist2 months ago

    Merck’s Segment-Wise Performance in 1Q18

    Merck’s (MRK) products are classified into four business segments: Human Pharmaceutical, Animal Health, Healthcare Services, and Alliances. Merck’s revenue grew 6% to ~$10.0 billion in 1Q18, driven by 3% operating revenue growth and a 3% boost by foreign exchange.

  • Allergan’s US Specialized Therapeutics Segment in 1Q18
    Market Realist2 months ago

    Allergan’s US Specialized Therapeutics Segment in 1Q18

    As we discussed previously in this series, Allergan’s (AGN) US Specialized Therapeutics segment includes the revenues from the US sales of specialized products related to eye care, medical aesthetics, dermatology, neuroscience, and urology. The chart below compares the revenues for the US Specialized Therapeutics segment since 1Q17.

  • Pfizer Reports 1Q18 Earnings and Revenue Growth
    Market Realist3 months ago

    Pfizer Reports 1Q18 Earnings and Revenue Growth

    Pfizer (PFE) released its 1Q18 earnings today, reporting another strong quarter for the Innovative health business. The company reported 1% growth in its revenues to $12.9 billion for 1Q18, compared to ~$12.8 billion in 1Q17.

  • Why Analysts Expect Pfizer to See Revenue Growth in 1Q18
    Market Realist3 months ago

    Why Analysts Expect Pfizer to See Revenue Growth in 1Q18

    As discussed in the previous part of this series, Wall Street analysts estimate Pfizer’s (PFE) revenues will increase ~2.7% to $13.1 billion during 1Q18 as compared to revenues of $12.8 billion during 1Q17. The growth in revenues is expected to be driven by innovative health products. Pfizer’s products are classified into two business segments: the Innovative Health segment and the Essential Health segment.

  • Allergan’s 1Q18 Estimates: Expect Growth in Revenues
    Market Realist3 months ago

    Allergan’s 1Q18 Estimates: Expect Growth in Revenues

    As we discussed earlier, analysts expect Allergan’s (AGN) revenues to see 0.6% growth to $3.6 billion during 1Q18. Allergan classifies its business operations into three business segments: US Specialized Therapeutics US General Medicines International 

  • Analysts Expect Bristol-Myers Squibb to Post Revenue Growth in 1Q18
    Market Realist3 months ago

    Analysts Expect Bristol-Myers Squibb to Post Revenue Growth in 1Q18

    As discussed, Bristol-Myers Squibb (BMY) is expected to report growth of ~6.3% to $5.2 billion in its 1Q18 earnings on April 26. The above graph shows the quarterly revenues of Bristol-Myers Squibb since 1Q17 and analysts’ estimates for 1Q18. Nearly 45% of total revenues for Bristol-Myers Squibb come from international sales, so the company is exposed to currency risk.

  • How Johnson & Johnson’s Medical Devices Segment Performed in 1Q18
    Market Realist3 months ago

    How Johnson & Johnson’s Medical Devices Segment Performed in 1Q18

    Johnson & Johnson’s (JNJ) medical devices business includes cardiovascular care products, orthopedics products, surgery products, vision care products, and diabetes products. The medical devices business reported 7.5% growth in revenues to $6.8 billion during 1Q18 as compared to revenues of $6.3 billion during 1Q17. The growth includes 3.2% growth in revenues at constant exchange rates and a 4.3% increase due to the positive impact of foreign exchange.

  • Should You Invest in the VanEck Vectors Pharmaceutical ETF (PPH)?
    Zacks3 months ago

    Should You Invest in the VanEck Vectors Pharmaceutical ETF (PPH)?

    Sector ETF report for PPH

  • Analysts’ Estimates for Eli Lilly & Co.’s 1Q18 Earnings
    Market Realist3 months ago

    Analysts’ Estimates for Eli Lilly & Co.’s 1Q18 Earnings

    Eli Lilly & Co. (LLY) is a leading US-based pharmaceutical company with a product portfolio covering human health products and animal health products. Eli Lilly is set to release its 1Q18 earnings on April 24.

  • Merck’s Relebactam Met Primary Endpoints in Phase 3 Study
    Market Realist3 months ago

    Merck’s Relebactam Met Primary Endpoints in Phase 3 Study

    Merck’s (MRK) Relebactam is an investigational beta-lactamase inhibitor for the treatment of certain forms of imipenem-non-susceptible bacterial infections.

  • How Merck & Co. Stock Performed in 1Q18
    Market Realist3 months ago

    How Merck & Co. Stock Performed in 1Q18

    Headquartered in New Jersey, Merck & Co. (MRK) is one of the oldest and largest pharmaceutical companies by revenue. Merck is doing business as Merck Sharp & Dohme outside the US and Canadian markets.

  • A Look at the 4Q17 Performance of Eli Lilly’s Elanco
    Market Realist4 months ago

    A Look at the 4Q17 Performance of Eli Lilly’s Elanco

    A Look at Eli Lilly's Performance from 4Q17 to the Present

  • What’s Merck’s Valuation in March 2018?
    Market Realist4 months ago

    What’s Merck’s Valuation in March 2018?

    What Analysts Recommend for Merck in March 2018

  • Eli Lilly’s Revenue in 4Q17
    Market Realist4 months ago

    Eli Lilly’s Revenue in 4Q17

    A Look at Eli Lilly's Performance from 4Q17 to the Present

  • A Look at Bristol-Myers Squibb’s 4Q17 Revenue
    Market Realist4 months ago

    A Look at Bristol-Myers Squibb’s 4Q17 Revenue

    What’s Behind Bristol-Myers Squibb’s Valuation

  • Pfizer’s Valuation Post-4Q17 Earnings
    Market Realist4 months ago

    Pfizer’s Valuation Post-4Q17 Earnings

    An Overview of Pfizer's 4Q17: What Lies Ahead?A look at Pfizer’s valuation

  • Analysts’ Estimates for Johnson & Johnson after 4Q17
    Market Realist4 months ago

    Analysts’ Estimates for Johnson & Johnson after 4Q17

    Changes in Johnson & Johnson's Valuation in February 2018

  • Johnson & Johnson’s Recent Developments
    Market Realist6 months ago

    Johnson & Johnson’s Recent Developments

    Must-Read Notes on Johnson & Johnson’s 4Q17 Earnings

  • Analysts’ Ratings and Recommendations for Eli Lilly
    Market Realist6 months ago

    Analysts’ Ratings and Recommendations for Eli Lilly

    A Preview of Eli Lilly’s 4Q17 Earnings Release on January 31

  • Merck’s & Co.’s Valuation in January 2018
    Market Realist6 months ago

    Merck’s & Co.’s Valuation in January 2018

    Who’s Watching Merck & Co. in January 2018?Merck & Co.’s valuation